38results about How to "Inhibition of chemotaxis" patented technology

There are provided uses of an antibody directed to CX3CR1 and fractalkine. Killer lymphocytes can be readily identified, eliminated and separated by using an anti-CX3CR1 antibody. Further, there can be provided an antibody drug for suppressing chemotaxis and cytotoxic activity of killer lymphocytes by suppressing an interaction between CX3CR1 and fractalkine.

The invention relates to a giant salamander Chinese herbal medicine compound preparation for treating hepatitis B. The preparation is prepared from giant salamander tissue and the following Chinese herbal medicines in parts by weight: 35-45 parts of medlar, 25-35 parts of lucid ganoderma, 10-14 parts of coptis chinensis, 13-16 parts of radix sophorae flavescentis, 10-14 parts of selfheal, 13-16 parts of radix scutellariae, 16-20 parts of isatis roots, 16-20 parts of honeysuckles, 8-12 parts of dendrobium officinale and 6-10 parts of ginseng, wherein the giant salamander tissue comprises 500-3000 parts of giant salamander liver and 5-9 giant salamander gallbladders. The preparation method of the preparation comprises the following steps: grinding and mixing the giant salamander tissue, steaming for 8-12 minutes at 85-95 DEG C and freezing to obtain a giant salamander tissue mixture; smashing medlar, lucid ganoderma, coptis chinensis, radix sophorae flavescentis, selfheal, radix scutellariae, isatis roots, honeysuckles, dendrobium officinale, ginseng and spiral seaweed to obtain a Chinese herbal medicine mixture; and mixing the giant salamander tissue mixture with the Chinese herbal medicine mixture. The preparation provided by the invention not only has a good antiviral performance, but also can effectively enhance the antigen binding affinity and the immunity to protect liver activity and promote recovery of damaged liver cells and the like. The preparation for treating hepatitis B is remarkable in curative effect.

The present invention relates to a novel biphenyl derivative or a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases comprising the same as an active ingredient, and methods for treating inflammatory disease or autoimmune diseases with the pharmaceutical composition. Novel biphenyl derivatives according to the present invention promote the phagocytosis of macrophages and inhibit the chemotaxis to exhibit excellent inflammation terminating and anti-inflammatory effects and thus can be effectively used as therapeutic agents for inflammatory diseases or autoimmune diseases.

Human and animal serum contains naturally occurring autoantibodies that develop at birth in absence of deliberate immunization. These antibodies are predominantly of IgM isotype but can include all immunoglobulin isotypes such as IgD, IgA and IgG. Here we describe IgM anti-lymphocyte autoantibodies (IgM-ALA) and show that these antibodies are heterogenous with some antibodies binding to chemokine receptors such as CCR5 and CXCR4 and others binding to other lymphocyte receptors including CD3, CD2, CD4 and CD81. These IgM-ALA, unlike IgG antibodies, are not cytolytic to cells at 37 C and hence function to alter lymphocyte function including cytokine production and act as “blocking antibodies to inhibit binding of chemokines and viruses including HIV-1 and Hepatitis C. IgM antibodies that bind to receptors on lymphocyte also bind to the same or similar class of receptors on other leucocytes and other cells such as cancer cells and endothelial cells. The inventor claims that naturally occurring anti-lymphocyte antibodies inhibit viral infections, cancer and several inflammatory states by binding to chemokine receptors and other cell membrane receptors that activate cells or promote viral entry and replication. Inventor also claims methods for quantitating levels of IgM-ALA with different receptor specificities to aid in preventing disease progression and also claims methods to enhance in-vivo or in-vitro production of IgM-ALA.

The present invention provides a long-acting heparin intraocular slow-releasing system, including heparin and medicinal carrier; their weight ratio is 0.1:0.9-0.9:0.1. Said medicinal carrier can be synthetic biodegradable high-molecular material, natural biodegradable high-molecular material or their mixture. The medicine-releasing period of said invented long-acting heparin slow-releasing systemis one week to one year. It can be used for inhibiting formation of antithrombase, resisting conversion of fibrinogen into insoluble fibrin, inhibiting proliferation and chemotaxis of fibrolast, reducing postoperative fibrinous exudation and preventing postcapsule opacity so as to inhibit the production of after-cataract.

The invention provides an oral giant salamander liquid for brain strengthening. The oral liquid is prepared through using the following raw materials, by weight, 150-250 parts of a giant salamander brain, 10-20 parts of a giant salamander liver, 4-8 parts of ginseng, 15-25 parts of Lycium Chinense, 25-35 parts of lotus seed, 8-12 parts of brown sugar, 8-12 parts of walnut kernel, 15-25 parts of Dioscorea opposita and 15-25 parts of red date. A preparation method of the oral liquid comprises the following steps: adding water having a weight 2-3 times raw materials except brown sugar to the raw materials except brown sugar, decocting with a slow fire for 1.5-2h, filtering, adding brown sugar, uniformly mixing, filtering, cooling, and canning. The oral liquid has the efficacies of essence replenishing, blood tonifying, brain strengthening, intelligence developing, liver and kidney nourishing, heart fire clearing, vexation eliminating, qi tonifying, blood nourishing and the like, and can be adapted to all age groups.

The invention discloses anti-inflammatory application of a small molecule compound AG-4, and application in preparing anti-inflammatory drug. The small molecule compound AG-4 is screened through a candidate drug screening platform combining structural biology, information biology and biological activity determination. The small molecule compound AG-4 can realize specific binding with CD147 protein to inhibit inflammatory cell chemotaxis and secretion of chemotaxis; the invention is also suitable for preparing medicines for treating CD147 protein high expression related diseases (such as rheumatoid arthritis).

The invention discloses an application of 1-(5-(3-((4-chlorobenzyl)amino)-2-hydroxypropoxy)-2-methyl-1-(p-tolyl)-1H-indol-3-yl) ethanone in treatment or prevention of inflammatory diseases. The compound is used for preventing and/or relieving and/or adjunctively treating and/or treating inflammatory diseases such as bronchitis, pneumonia, hepatitis, rhinitis, enterogastritis, gastritis, nephritis,dermatitis, prostatitis, vaginitis, rheumatism and the like. The 1-(5-(3-((4-chlorobenzyl)amino)-2-hydroxypropoxy)-2-methyl-1-(p-tolyl)-1H-indol-3-yl) ethanone has a specific inhibition effect on PI3K gamma and has an inhibition effect on inflammatory cell proliferation and chemotaxis. The compound can inhibit inflammatory response by inhibiting the PI3K gamma.

The invention discloses an aquaporin 4-siRNA interfering sequence, its fusion expression vectors and a medicinal use of the fusion expression vectors, and belongs to the biopharmaceutical field. In the invention, an aquaporin 4-siRNA interfering sequence is designed and fusion expression vectors of the aquaporin 4-siRNA interfering sequence are synthesized. After the fusion expression vectors are transfected into human glioma cell lines, the fusion expression vectors can degrade specifically aquaporin 4mRNA which is complementary with the fusion expression vectors, decrease the expression of an aquaporin protein 4 in a human glioma cell, inhibit effectively a migration capacity, an adhesive capacity and an invasion capacity of human glioma cells and have effects of inhibiting the infiltration and the diffusion of human glioma cells thus provide a feasible technical means for a gene therapy utilized for tumor patients.

The invention discloses a composition capable of enabling the skin to defend pigments, and application. The composition comprises 1-4% of glutathione, 1-3% of arbutin, 0.2-0.6% of vitamin C, 0.1-2% ofvitamin E, 0.05-0.1% of indomethacin, 0.01-0.05% of 9-carotene, 0.1-0.6% of green tea, 0.2-0.7% of fructus mume extract, 0.2-0.9% of cortex cinnamomi extract, 2-12% of glycyrrhizae radix oil, 1-6% ofsoluble extract and the balance of water. Since the glutathione and the arbutin are added, formation of melanin is inhibited and disturbed so as to reduce skin pigment deposition and remove colored patches and freckles, the vitamin C, the vitamin E, the fructus mume extract and the soluble extract are combined to increase oxidation resistance capacity, the composition is prevented from being oxidized, the composition is guaranteed to still own an effect of inhibiting the formation of the melanin in the sun, and the skin fully defends the pigments.

The invention discloses a preparation method of a medical adhesive with efficient anti-inflammation and bleeding-stopping functions. The medical adhesive is characterized by containing the following components in parts by weight: 20-25 parts of alpha-octyl cyanoacrylate, 25-35 parts of alpha-isoctyl cyanoacrylate, 2-6 parts of polyvinyl acetate, 12-20 parts of an efficient anti-inflammation component, 13-23 parts of an efficient bleeding-stopping component, 3-6 parts of a cell activator MG-60, 8-10 parts of allantoin, 1 part of hydrolyzed wheat proteins, 1 part of a stabilizer, 150-220 parts of a compound anti-inflammation fruit oil component and 200 parts of sterile water. By particularly selecting multiple extracts with the anti-inflammation and bleeding-stopping functions and adding twoefficient anti-inflammation components and one efficient bleeding-stopping component, the integral anti-inflammation and bleeding-stopping effects of the medical adhesive are improved, and the medical adhesive is high in bonding strength, short in bleeding-stopping time and accordant with clinical application requirements on medical adhesives.

The invention discloses a medical adhesive with efficient anti-inflammation and hemostasis functions. The medical adhesive is characterized by comprising, by weight, 20-25 parts of alpha-N-octyl cyanoacrylate, 25-35 parts of alpha-isooctyl cyanoacrylate, 2-6 parts of polyvinyl acetate, 12-20 parts of efficient anti-inflammation components, 13-23 parts of efficient hemostasis components, 3-6 partsof cell activators MG-60, 8-10 parts of allantoin, 1 part of hydrolyzed wheat protein, 1 part of stabilizers, 150-220 parts of compound anti-inflammatory fruit oil components and 200 parts of sterilewater. The medical adhesive particularly selects various extracts with the anti-inflammation and hemostasis functions, two efficient anti-inflammation components and one efficient hemostasis componentare added, so that overall anti-inflammation and hemostasis effects are improved, and the medical adhesive is high in bonding strength and short in hemostasis time and meets application requirementsof clinical medical adhesives.

The invention discloses stype with good effects of eliminating inflammation, relieving pain and stopping bleeding and a preparation method of the stype. The stype is prepared from the following components in parts by weight: 2-15 parts of cassia twigs, 2-15 parts of rhizoma corydalis, 5-16 parts of garden burnet, 2-10 parts of rhizoma acori graminei, 2-10 parts of borneol, 2-10 parts of radix saposhnikoviae, 1-10 parts of gallnuts, 2-12 parts of angelica sinensis, 2-12 parts of pseudo-ginseng and 2-16 parts of indometacin. By adopting the stype, the problems that a single western medicine is serious in toxic and side effect and a single traditional Chinese medicine is poor in treatment effect, are effectively solved. Effects of spasmolysis and pain relieving, inflammation elimination and detoxication, blood activation and stasis removal, bleeding stopping and blood enrichment, and the like, are highlighted, anorectum administration is carried out, meanwhile with a dredging function ofresuscitation-inducing aromatic herbs, effective components of medicines are conveyed to different tissue organs through main and collateral channels to adjust and nourish bodies, damage of western medicines to organs such as stomachs, intestines, livers, kidneys, hearts and brains is relieved, and the stype is convenient to administrate, rapid in absorption, rapid in effect taking, good in pain relieving effect, small in toxic and side effect, free of addiction, free of dependency, safe and reliable, and is ideal stype for spasmolysis and pain relieving, blood activation and stasis removal, and bleeding stopping and inflammation elimination.

Provided are assays and methods of identifying antiangiogenic agents including contacting an endothelial cell with a putative antiangiogenic agent and assaying for activation of Rap-1 in the endothelial cell. Also provided are methods of inhibiting angiogenesis and treating conditions associated with improper angiogenesis. Compositions comprising activators of Rap-1 and methods of activating the Rap-1 signaling pathway are also provided. Methods of inhibiting chemotaxis and angiogenesis by contacting cells with Rho inhibitors are provided.